PolyPid - Asset Resilience Ratio
PolyPid (PYPD) has an Asset Resilience Ratio of 29.28% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check PolyPid strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how PolyPid's Asset Resilience Ratio has changed over time. See PolyPid (PYPD) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down PolyPid's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of PolyPid.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $6.53 Million | 29.28% |
| Total Liquid Assets | $6.53 Million | 29.28% |
Asset Resilience Insights
- Very High Liquidity: PolyPid maintains exceptional liquid asset reserves at 29.28% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
PolyPid Industry Peers by Asset Resilience Ratio
Compare PolyPid's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for PolyPid (2016–2025)
The table below shows the annual Asset Resilience Ratio data for PolyPid.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 29.28% | $6.53 Million | $22.31 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $15.37 Million | -- |
| 2022-12-31 | 15.56% | $4.04 Million | $25.97 Million | -35.04pp |
| 2021-12-31 | 50.60% | $22.38 Million | $44.23 Million | -2.34pp |
| 2020-12-31 | 52.94% | $40.16 Million | $75.85 Million | -14.24pp |
| 2019-12-31 | 67.18% | $22.68 Million | $33.77 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $14.48 Million | -- |
| 2017-12-31 | 61.05% | $14.03 Million | $22.98 Million | +21.90pp |
| 2016-12-31 | 39.14% | $7.53 Million | $19.24 Million | -- |
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients unde… Read more